Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology

Contemporary Clinical Trials

Volumn 34, Issue 2, 2013, Pages 196-204

  Mooney, Larissa J ^a   Nielsen, Suzanne ^b   Saxon, Andrew ^c,d   Hillhouse, Maureen ^a   Thomas, Christie ^a   Hasson, Albert ^a   Stablein, Don ^e   McCormack, Jennifer ^e   Lindblad, Robert ^e   Ling, Walter ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e EMMES CORPORATION   (United States)

Author keywords

Buprenorphine; Clinical Trials Network; Cocaine dependence; Kappa antagonist; Methods; Naltrexone

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; NALTREXONE; PLACEBO;

ARTICLE; COCAINE DEPENDENCE; COGNITIVE THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPIATE ADDICTION; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; AGED; BUPRENORPHINE; COCAINE-RELATED DISORDERS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871643655     PISSN: 15517144     EISSN: 15592030     Source Type: Journal    
DOI: 10.1016/j.cct.2012.11.002     Document Type: Article

References (30)

1. Substance Abuse and Mental Health Services Administration Treatment outcomes among clients discharged from outpatient substance abuse treatment Retrieved December 6th 2011, 2011, from. http://www.oas.samhsa.gov/2k9/outptTX/outptTX.htm.
2. Substance Abuse and Mental Health Services Administration, O.A.S. Drug Abuse Warning Network, Detailed Tables: National Estimates of Drug-Related Emergency Department Visits 2004-2008 Data retrieved 7/20/2010. https://dawninfo.samhsa.gov/data/.
3. Lufty K., Eltan S., Bryant C., Yang Y.C., Saliminejad N., Walwyn W., et al. Buprenorphine-induced antinociception is mediated by μ-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 2003, 23(32):10331-10337.
4. Montoya I., Gorelick D.A., Preston K.L., et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther 2004, 75(1):34-48.
5. Schottenfeld R.S., Pakes J., Ziedonis D., Kosten T.R. Buprenorphine: dose-related effects on cocaine and opioid use in cocaine-abusing opioid-dependent humans. Biol Psychiatry 1993, 34(1-2):66-74.
6. Karila L., Gorelick D., Weinstein A., Noble F., Benyamina A., Coscas S., et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008, 11(03):425-438.
7. Somaini L., Donnini C., Raggi M.A., Amore M., Ciccocioppo R., Saracino M.A., et al. Promising medications for cocaine dependence treatment. Recent Pat CNS Drug Discov 2011, 6(2):146-160.
8. Rothman R.B., Gorelick D.A., Heishman S.J., Eichmiller P.R., Hill B.H., Norbeck J., et al. An open-label study of a functional opioid κ antagonist in the treatment of opioid dependence. J Subst Abuse Treat 2000, 18(3):277-281.
9. Gerra G., Fantoma A., Zaimovic A. Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006, 20(6):806-814.
10. Guidance for industry E6 good clinical practice: consolidated guidance Apr. 1996, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics and Evaluation, Rockville, MD.
11. Rawson R.A., Marinelli-Casey P., Anglin M.D., Dickow A., Frazier Y., Gallagher C., et al. A multi-site comparison of psychosocial approaches for the treatment of methamphetamine dependence. Addiction 2004, 99:708-717.
12. Fals-Stewart W., O'Farrell T.J., Freitas T.T., McFarlin S.K., Rutigliano P. The Timeline Followback reports of psychoactive substance use by drug-abusing patients: psychometric properties. J Consult Clin Psychol 2000, 68(1):134-144.
13. Sobell L.C., Sobell M.B. Timeline Follow-back: a technique for assessing self-reported ethanol consumption. Measuring alcohol consumption: psychosocial and biological methods 1992, 41-72. Humana Press. R.Z. Litten, J.P. Allen (Eds.).
14. Ling W., Shoptaw S., Wesson D., Rawson R.A., Compton M., Klett C.J. Treatment effectiveness score as an outcome measure in clinical trials. NIDA Res Monogr 1997, 175:208-220.
15. McMillan D.E., Gilmore-Thomas K. Stability of opioid craving over time as measured by visual analog scales. Drug Alcohol Depend 1996, 40:235-239.
16. Beck A.T., Steer R.A. Beck Depression Inventory Manual 1993, Harcourt Brace & Company, New York.
17. The WHOQOL Group Development of the WHOQOL-BREF Quality of Life Assessment. Psychol Med 1998, 28:551-558.
18. Skevington S.M., Lofty M., O'Connell K., The WHOQOL Group The World Health Organisation's WHOQOL-Bref quality of life assessment: Psychometric properties and the results of the international field trial. A report from the WHOQOL Group. Qual Life Res 2004, 13(2):299-310.
19. Ling W. The treatment effects assessment 2009, UCLA Integrated Substance Abuse Programs.
20. Navaline H.A., Snider E.C., Petro C., Tobin D., Metzger D., Alterman A., et al. An automated version of the Risk Assessment Battery (RAB): enhancing the assessment of risk behaviors. AIDS Res Hum Retroviruses 2004, 10(2).
21. McLellan A.T., Kushner H., Metzger D., Peters R., Smith I., Grissom G., et al. The fifth edition of the addiction severity index. J Subst Abuse Treat 1992, 9(3):199-213.
22. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerström K.O. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991, 1119-1127.
23. Hasin D.S., Trautman K.D., Miele G.M., Samet S., Smith M., Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry 1996, 153(9):1195-1201.
24. Oden N.L., VanVeldhuisen P.C., Wakim P.G., Trivedi M.H., Somoza E., Lewis D. Power of automated algorithms for combining time line follow back and urine drug screening test results in stimulant-abuse clinical trials. Am J Drug Alcohol Abuse 2011, 37:350-357.
25. Little K.Y., Ramsen E., Welchko R., Volberg V., Roland C.J., Cassin B. Decreased brain dopamine cell numbers in human cocaine users. Psychiatry Res 2009, 168(3):173-180.
26. Spanagel R., Herz A., Shippenberg T. Opposing tonically active endogenous opioid systems modulate the mesolimbic dopamine pathway. Proc Natl Acad Sci 1992, 89:2046-2050.
27. Beardsley P., Pollard G., Howard J., Carroll F. Effectiveness of analogs of the kappa opioid receptor antagonist (3R)-7-Hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic) to reduce U50,488-induced diuresis and stress-induced cocaine reinstatement in rats. Psychopharmacology 2010, 210(2):189-198.
28. Frankel P.S., Alburges M.E., Bush L., et al. Striatal and ventral pallidum dynorphin concentrations are markedly increased in human chronic cocaine users. Neuropharmacology 2008, 55(1):41-46.
29. Beardsley P., Howard J., Shelton K., Carroll F. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology 2005, 183(1):118-126.
30. Wee S., Vendruscolo L.F., Misra K.K., Schlosburg J.E., Koob G.F. A combination of buprenorphine and naltrexone blocks compulsive cocaine intake in rodents without producing dependence. Sci Transl Med 2012, 4(146):146ra110.